FeesSafety
Pluang+

Montauk Renewables delays capital spending, seeks credit amendments amid operational challenges.

Company Fundamentals
19 Nov 2026, 07:27 WIB
The Motley Fool Team
View Source
Neutral
Montauk Renewables delays capital spending, seeks credit amendments amid operational challenges.

Montauk Renewables deferred up to $120 million in capital spending and is negotiating credit facility amendments due to operational delays at its North Carolina swine waste project. These delays have created short-term risks for debt covenants, requiring about $15 million and three months to address feedstock moisture and temperature issues. Meanwhile, its GreenWave joint venture distributed 1.1 million Renewable Identification Numbers, boosting revenue. The company reaffirmed its full-year renewable natural gas production and revenue outlook, focusing on liquidity management and expanding agricultural renewable energy projects and partnerships.

Montauk Renewables is the subject of this update. For readers following the energy sector, here is Pluang's market snapshot as of Nov 19, 2026 07:11 WIB: Out of 79 priced US energy stocks, 8 rose and 71 fell. Occidental Petroleum Corporation (OXY) traded at USD 53.92 with a 1-day change of -4.59% and a typical hold time of 94 days. Canadian Natural Resources Ltd. (CNQ) was priced at USD 45.56, down 4.57%, with 100% buy orders. Chevron Corp (CVX) stood at USD 206.40, down 4.50%, with 56% sell orders.

More News

Micron's strong growth and rising stock price hint at a possible future stock split.

Micron's strong growth and rising stock price hint at a possible future stock split.

Micron Technology is showing strong financial growth, driven by its crucial role in AI infrastructure and multiyear deals with key tech companies. The company recently beat revenue expectations with a 379% year-over-year increase and projects even be...

Company Fundamentals
Bullish
29 minutes ago
FDA approves Livsayis™, first siRNA therapy for generalized myasthenia gravis, offering new treatment option.

FDA approves Livsayis™, first siRNA therapy for generalized myasthenia gravis, offering new treatment option.

The FDA has approved Livsayis™ (cemdisiran), the first and only siRNA therapy for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody-positive. This subcutaneous treatment, administered four times a year, targ...

Market News
Bullish
38 minutes ago
Elauwit reports 66% growth in monthly recurring revenue to $539K, cutting expenses and expanding managed Wi-Fi networks.

Elauwit reports 66% growth in monthly recurring revenue to $539K, cutting expenses and expanding managed Wi-Fi networks.

Elauwit announced a 66% year-over-year increase in monthly recurring revenue to $539,000 by the end of Q3 2026, driven by long-term contracts for managed Wi-Fi in apartment communities. The company also reduced operating expenses by 19% sequentially ...

Company Fundamentals
Bullish
44 minutes ago
Palantir's revenue soars past $2B, outpacing UiPath's slower, seasonal growth in AI software sales.

Palantir's revenue soars past $2B, outpacing UiPath's slower, seasonal growth in AI software sales.

Palantir Technologies has shown rapid quarter-over-quarter revenue growth, reaching $2.3 billion in Q3 2026, driven by strong commercial adoption of its AI platform and expansion beyond government contracts. In contrast, UiPath's revenue growth is mo...

Market News
Bullish
47 minutes ago
Anthropic's IPO may see high demand and price growth despite lower AI investment interest.

Anthropic's IPO may see high demand and price growth despite lower AI investment interest.

Anthropic is launching its IPO with an initial price of $83, but shares may trade higher on the open market due to strong demand. Although AI investment interest has cooled, Anthropic's rapid revenue growth—12 times year-over-year to $17 billion in Q...

Market News
Bullish
51 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App